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Abstract
Background Skeletal muscle wasting is an extremely common feature in patients with heart failure, affecting approximately
20% of ambulatory patients with even higher values during acute decompensation. Its occurrence is associated with reduced
exercise capacity, muscle strength, and quality of life. We sought to investigate if the presence of muscle wasting carries prog-
nostic information.
Methods Two hundred sixty-eight ambulatory patients with heart failure (age 67.1 ± 10.9 years, New York Heart Association
class 2.3 ± 0.6, left ventricular ejection fraction 39 ± 13.3%, and 21% female) were prospectively enrolled as part of the Studies
Investigating Co-morbidities Aggravating Heart Failure. Muscle wasting as assessed using dual-energy X-ray absorptiometry
was present in 47 patients (17.5%).
Results During a mean follow-up of 67.2 ± 28.02 months, 95 patients (35.4%) died from any cause. After adjusting for age,
New York Heart Association class, left ventricular ejection fraction, creatinine, N-terminal pro-B-type natriuretic peptide, and
iron deficiency, muscle wasting remained an independent predictor of death (hazard ratio 1.80, 95% confidence interval 1.01–
3.19, P = 0.04). This effect was more pronounced in patients with heart failure with reduced than in heart failure with pre-
served ejection fraction.
Conclusions Muscle wasting is an independent predictor of death in ambulatory patients with heart failure. Clinical trials are
needed to identify treatment approaches to this co-morbidity.
Keywords Wasting; Sarcopenia; Cachexia; Heart failure; Survival
Received: 22 April 2020; Revised: 2 June 2020; Accepted: 8 June 2020
*Correspondence to: Prof. Stephan von Haehling, Department of Cardiology and Pneumology, University of Göttingen Medical Center, Robert-Koch-Straße 40, D-37075,
Göttingen, Germany. Phone: +49 551 39 20911, Fax: +49 551 39 20918, Email: stephan.von.haehling@web.de
Introduction
Heart failure (HF) has huge socio-economic impact and is as-
sociated with high morbidity and mortality. Likewise, patients
often present with reduced quality of life and low exercise
capacity as can be directly measured or extrapolated from
breathlessness and fatigability. In addition, most patients
present with co-morbidities that directly or indirectly worsen
exercise tolerance, morbidity, and/or mortality. Among
these, atrial fibrillation, diabetes mellitus, chronic obstructive
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pulmonary disease, sleep-disordered breathing, iron defi-
ciency, and chronic kidney disease play important roles. Re-
cently, skeletal muscle wasting has emerged as an important
co-morbidity of HF1 that affects both patients with HF with
preserved ejection fraction (HFpEF) and those with HF with re-
duced ejection fraction (HFrEF) in that it further reduces low
peak oxygen consumption, 6 min walk distance, and handgrip
as well as quadriceps strength.2–4 The prevalence of skeletal
muscle wasting has been reported to be 19–52% among all
patients with HF. The large range mirrors the association with
the cohort under investigation. For example, stable
ambulatory patients seem to have lower prevalence values
than patients with acute or advanced HF,5–7 and patients with
dilated cardiomyopathy may have higher prevalence values
than patients with ischaemic heart disease.2,3,8
It is important to note that skeletal muscle wasting, in geriat-
ric populations commonly called sarcopenia, is different from
cachexia, because only cachexia is by definition associated with
weight loss.4 Recent data have shown that cachexia in patients
with HF, usually termed cardiac cachexia, can be associated
with skeletal muscle wasting; however, this is not a prerequi-
site, because also fat tissue and bone mineral density can be di-
minished during these catabolic wasting processes.9 Reduced
exercise performance, however, is primarily present in those
patients who have lost skeletal muscle.10 This finding coincides
with reduced peripheral blood flow in patients with muscle
wasting.11 Interestingly, mitochondrial energy production can
be improved in the skeletal muscle by intravenous iron therapy
in patients with iron deficiency,12 underlining the importance of
iron provision for energy production in this system. Treatment
of muscle wasting and iron deficiency may provide an interest-
ing means to improve exercise capacity and quality of life, both
of which are difficult to increase using guideline -recommended
HF treatments.12
It has long been established that cardiac cachexia is
associated with reduced survival, and this finding is indepen-
dent of other prognostic factors such as age, reduced peak
oxygen consumption, left ventricular ejection fraction (LVEF),
or New York Heart Association (NYHA) class.13 The aim of the
present analysis from the Studies Investigating Co-morbidities
Aggravating Heart Failure (SICA-HF) was to test whether
skeletal muscle wasting itself carries prognostic information
in patients with HF, irrespective of whether HFrEF or HFpEF
is present.
Methods
Study population
Patients were prospectively enrolled as part of SICA-HF at the
Department of Cardiology, Charité Medical School, Campus
Virchow-Klinikum, Berlin, Germany, between February 2010
and March 2014. All subjects provided written informed
consent before being enrolled. The local ethics committee
approved the study, which was funded by the European
Commission’s Seventh Framework Programme (FP7/2007-
2013) under Grant Agreement Number 241558. All principles
of the Declaration of Helsinki were fulfilled. Clinical data from
this dataset have been published before and have served to
characterize body composition as well as clinical features of
patients with wasting disorders in HF.2,3,11
The inclusion criteria of SICA-HF were broad and have been
published before.14 In brief, patients were eligible if the
following criteria were met: age >18 years, clinical signs
and symptoms of chronic HF with LVEF ≤ 40% (HFrEF) or with
an LVEF > 40%, and a left atrial dimension ≥4.0 cm (HFpEF).
Exclusion criteria embraced previous heart transplantation,
cardiac or embolic events within 6 weeks prior to the baseline
examination, and patients on haemodialysis or with known
pregnancy. Transthoracic two-dimensional echocardiography
was performed before entering the study to assess standard
cardiac parameters including LVEF using Simpson’s biplane
technique. Blood was drawn for serum and plasma sampling
early in the morning after an overnight fast and after at least
15 min of supine rest. In addition, standard parameters were
assessed including a full blood count and routine clinical
biochemistry parameters.
Definition of wasting
All patients underwent standardized procedures to assess mus-
cle mass and body weight. Dual-energy X-ray absorptiometry
(DEXA) was used to assess body composition. Like in previous
publications from this dataset, muscle wasting was defined ac-
cording to previously published criteria suggested to diagnose
sarcopenia,15 that is, an appendicular skeletal muscle mass 2
SDs below the mean of a healthy young reference group aged
18–40 years. This translates into an appendicular skeletal mus-
cle mass below 7.26 kg in men or 5.45 kg in women.16
Appendicular lean mass was defined as the lean mass of both
arms and legs combined. Lean mass data from DEXA scan were
evaluated, and the patients’ muscle mass index was
calculated.17 This index assesses appendicular skeletal muscle
mass (ASM in kg), calculated as the lean muscle mass of both
arms and legs divided by height (in m) squared.18 A DEXA scan-
ner model ‘lunar prodigy’ was used with ‘lunar en Core 2002’
software (both from GE Medical Systems, Madison, WI, USA).
Body weight was assessed after an overnight fast wearing light
clothing without shoes on standardized weighing scales.
Clinical biochemistry
Iron deficiency was defined as recommended in the guide-
lines of the European Society of Cardiology as serum ferritin
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<100 ng/mL or serum ferritin 100–299 ng/mL with transferrin
saturation <20%. N-terminal pro B-type natriuretic peptide
was assessed on the Elecsys system using Roche assays
(Roche, Basel, Switzerland). The glomerular filtration rate
was calculated using the Chronic Kidney Disease Epidemiol-
ogy Collaboration formula.
Survival
Patients were followed until August 2018 when the database
was censored and for a mean of 67.2 ± 28.0 months or until
death. All survivors were followed for at least 100 months.
Statistical analysis
Baseline characteristics are expressed as mean ± standard
deviation or as number of patients with percentage. Unpaired
Student’s t-test and Fisher’s exact test were used to analyse
the difference between groups. N-terminal pro-B-type natri-
uretic peptide (NT-proBNP) was not normally distributed
and therefore transformed by logarithm of 10 in order to
achieve normal distribution. To estimate the influence of risk
factors, Cox proportional hazard analysis was performed,
firstly as single-predictor (or unadjusted) model und subse-
quently as multivariate (or adjusted) model. All statistical
analyses were performed using the Statistical Package for
the Social Sciences for Windows (IBM SPSS Statistics Version
25, IBM Corporation, Armonk, NY, USA). We considered a
two-tailed P-value <0.05 as statistically significant.
Results
Study population
A total of 268 patients were enrolled, 87 of whom had HFpEF
and 181 had HFrEF. The majority of patients were male;
however, the proportion of female vs. male was higher in
patients with HFpEF than in HFrEF (Table 1). Most patients
had ischaemic heart disease and were in NYHA Classes II
and III. Co-morbidities were highly prevalent; in particular,
patients had a high prevalence of diabetes mellitus (41%),
hypertension (81%), and atrial fibrillation (38%); 61.3% of pa-
tients with HFrEF had received a device implantation as
detailed in Table 1; as expected, this proportion was
significantly lower among patients with HFpEF.
Muscle wasting was present in 47 patients (17.5%), 39 of
whom had HFrEF and 8 of whom had HFpEF (P = 0.016).
Overall, patients with muscle wasting were older, were more
likely to be male, had a higher NT-proBNP value, were more
likely to be iron deficient, and were more likely to be anaemic
(Table 2). No major difference was detected for kidney
function between patients with vs. without muscle wasting,
but patients with muscle wasting tended to be more symp-
tomatic as highlighted by a trend towards higher NYHA class
(Table 2). More than 50% of the overall population were
found to be iron deficient being present in 95 of 181 patients
with HFrEF (52.5%) and in 42 of 87 patients with HFpEF
(48.8%, P = 0.6).
Survival analysis
A total of 95 patients (35.5%) died during a mean follow-up of
67.2 ± 28.02 months, 25 (9.3%) of whom had muscle wasting.
Kaplan–Meier analyses for mortality revealed a 12 month
mortality rate of 4.9% [95% confidence interval (CI) 2.16–
7.64%] and a 24 month mortality rate of 12.2% (95% CI
8.08–16.32%). This proportion was significantly higher in
patients with muscle wasting: Kaplan–Meier analyses for
mortality revealed a 12 month mortality rate of 11.11%
(95% CI 1.89–20.3%) in patients with muscle wasting
compared with 3.5% (95% CI 0.95–6.05%) and a 24 month
mortality rate of 22.22% (95% CI 10.05–34.35%) in compari-
son with 10% (95% CI 5.89–14.12%) in those without
(P = 0.003, Figure 1). Not surprisingly, survivors had a lower
mean NT-proBNP of 885.5 ± 1630 ng/L as compared with
2374.6 ± 3389.1 ng/L in non-survivors (P = 0.001).
Several baseline variables were investigated with regard to
their impact on all-cause death using single-predictor Cox
proportional hazard analysis: age, NYHA class, LVEF, serum
creatinine, NT-proBNP, the presence of iron deficiency, and
the presence of muscle wasting all predicted survival (Table
3 and Figure 1) and were entered into a multivariable model.
After adjusting for all the aforementioned variables, LVEF,
serum creatinine, and the presence of muscle wasting
remained independent predictors of death. Splitting the
models according to the presence of HFpEF or HFrEF showed
that in patients with HFpEF, serum creatinine remained the
only independent predictor of death, whereas in patients
with HFrEF, LVEF and muscle wasting remained independent
predictors of death; however, in this model, also a trend
existed towards significance for advancing age (Table 3).
Kaplan–Meier survival curves were constructed for illustrative
purposes and showed an early separation of the survival
lines (Figure 1).
Discussion
We show here that skeletal muscle wasting, as defined using
the cut-off values for sarcopenia, is an independent predictor
of death in a mixed cohort of patients with HF. This effect was
predominantly driven by patients with HFrEF who repre-
sented the majority of patients under study in the present
analysis. In patients with HFpEF, the minority of patients with
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lower event rate, muscle wasting did not remain an indepen-
dent predictor of death after multivariable adjustment, most
probably a reflection of the overall low event rate in this
cohort.
Data are accumulating to suggest that catabolic wasting
processes are present in advanced HF. These probably in-
clude activation of pro-inflammatory cytokines, low anabolic
drive,19 growth hormone resistance, and overactivity of the
renin–angiotensin–aldosterone system. The net result is loss
of functioning skeletal muscle via the ubiquitin–proteasome
system, autophagy, and increased myocyte apoptosis.4 It is
assumed that skeletal muscle as one of the main energy de-
pots of the human muscle is lost earlier than other tissues like
adipose tissue or even bone mineral density.9 However, the
latter two are also affected in patients with manifest cachexia
in advanced HF in whom tissue loss is so advanced that
affected patients are losing body weight. One of the main
challenges remains therefore to identify patients early and
before weight loss becomes apparent. Our present study un-
derscores the assumption that the loss of skeletal muscle
Table 1 Baseline characteristics of the study population
All patients (n = 268) HFpEF (n = 87) HFrEF (n = 181) P-value
Baseline demographics
Age (years) 67.14 ± 10.86 68.48 ± 11.33 66.49 ± 10.61 0.16
Sex (% female) 57 (21.3%) 29 (33.3%) 28 (15.5%) 0.001
Aetiology (% ischaemic) 162 (60.4%) 40 (46%) 122 (67.4%) <0.001
BMI (kg/m2) 28.95 ± 5.03 30.35 ± 4.94 28.27 ± 4.94 0.001
Systolic blood pressure (mmHg) 127.43 ± 22.94 138.86 ± 22.88 121.87 ± 20.86 <0.001
Diastolic blood pressure (mmHg) 75.04 ± 12.55 78.34 ± 13.49 73.43 ± 11.78 0.003
Heart rate (b.p.m.) 65.12 ± 10.76 63.69 ± 11.30 65.82 ± 10.45 0.14
LVEF (%) 39.00 ± 13.25 55.29 ± 5.96 31.17 ± 7.31 <0.001
NYHA class 2.32 ± 0.63 2.17 ± 0.66 2.39 ± 0.60 0.007
Medical history and co-morbidities
Diabetes mellitus (%) 109 (41.3%) 40 (47.6%) 69 (38.3%) 0.18
Hypertension (%) 214 (80.8%) 77 (90.6%) 137 (76.1%) 0.005
Previous myocardial infarction (%) 129 (49.6%) 23 (26.7%) 106 (61%) <0.001
Previous percutaneous intervention (%) 126 (48.8%) 32 (36.8%) 94 (55%) 0.008
Previous CABG procedure (%) 54 (21.1%) 12 (14.1%) 42 (24.6%) 0.07
Atrial fibrillation (%) 101 (38.1%) 26 (30.2%) 75 (41.9%) 0.08
Muscle wasting (%) 47 (17.5%) 8 (9.2%) 39 (21.5%) 0.02
Iron deficiency (%) 137 (51.3%) 42 (48.8%) 95 (52.5%) 0.6
Anaemia (%) 81 (30.2%) 22 (25.3%) 59 (32.6%) 0.26
Cachexia (%) 52 (20.2%) 10 (11.8%) 42 (24.3%) 0.021
Device implantation (%) 125 (46.6%) 14 (16.1%) 111 (61.3%) <0.001
ICD (%) 56 (44.8%, n = 125) 2 (14.3%, n = 14) 54 (48.6%, n = 111) 0.02
CRT-P or CRT-D (%) 50 (40%, n = 125) 5 (35.7%, n = 14) 45 (40.5%, n = 111) 0.78
Pacemaker (%) 19 (15.2%, n = 125) 7 (50%, n = 14) 12 (10.8%, n = 111) 0.001
Medication
ACE inhibitor or ARB (%) 251 (93.7%) 78 (89.7%) 173 (95.6%) 0.11
Beta-blocker (%) 239 (89.2%) 67 (77%) 172 (95%) <0.001
Mineralocorticoid receptor antagonist (%) 123 (45.9%) 18 (20.7%) 105 (58%) <0.001
Loop diuretic (%) 147 (55.1%) 30 (34.5%) 117 (65%) <0.001
Thiazide (%) 80 (29.9%) 34 (39.1%) 46 (25.4%) 0.03
Oral anticoagulant (%) 90 (33.8%) 19 (22.1%) 71 (39.4%) 0.006
Aspirin or clopidogrel (%) 192 (71.6%) 53 (60.9%) 139 (76.8%) 0.009
Statin (%) 184 (68.7%) 53 (60.9%) 131 (72.4%) 0.07
Digitalis (%) 29 (10.8%) 5 (5.7%) 24 (13.3%) 0.09
Laboratory parameters
Haemoglobin (g/dL) 13.42 ± 1.51 13.41 ± 1.42 13.42 ± 1.55 0.96
Leucocytes (/nL) 6.94 ± 2.03 6.63 ± 1.76 7.09 ± 2.13 0.1
Platelets (/nL) 222.62 ± 68.77 223.12 ± 52.38 222.38 ± 75.52 0.9
Sodium (mmol/L) 141.39 ± 4.04 142.37 ± 3.81 140.92 ± 4.07 0.007
Potassium (mmol/L) 4.49 ± 0.57 4.44 ± 0.51 4.51 ± 0.60 0.6
Creatinine (mg/dL) 1.186 ± 0.43 1.08 ± 0.34 1.24 ± 0.46 0.02
GFR (CKD-EPI, mL/min) 59.66 ± 14.84 62.09 ± 13.59 58.51 ± 15.3 0.1
Serum ferritin (μg/L) 86.54 ± 32.0 90.11 ± 32.86 84.85 ± 31.53 0.2
TSAT (%) 23.53 ± 9.92 25.57 ± 10.58 22.57 ± 9.46 0.02
Transferrin (mg/dL) 270 ± 49.3 257.93 ± 46.14 275.73 ± 49.84 0.006
NT-proBNP (ng/L) 1478 ± 2696 403 ± 498 2113 ± 3219 <0.001
Albumin (g/L) 37.05 ± 3.76 37.26 ± 3.43 36.95 ± 3.91 0.535
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; CABG, coronary artery bypass grafting;
CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; CRT-D, cardiac resynchronization therapy- defibrillator; CRT-P, cardiac
resynchronization therapy- pacemaker; GFR, glomerular filtration rate; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart
failure with reduced ejection fraction; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; NT-proBNP,
N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; TSAT, transferrin saturation.
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without manifest weight loss already identifies patients at in-
creased risk of death. Indeed, cardiac cachexia had already
been described as an independent predictor of death more
than 20 years ago, but it is now becoming clear that skeletal
muscle plays a pivotal role in this setting, because patients
who lose muscle are unable to exercise to a sufficient degree
as highlighted by low quality of life. Apart from those named
earlier, mechanisms involve reduced peripheral blood flow,11
abnormal ergoreflex physiology,20 and altered nutritional
intake,21 but probably also iron deficiency and anaemia.22,23
In particular, iron deficiency has been shown to have effects
in skeletal muscle, because enzymes of the mitochondrial
electron transport chain are iron dependent, and recent data
show that iron administration can help to improve phospho-
creatine recovery in the muscle.24
Previous studies have aimed to use skeletal muscle mass as
a predictor of death in patients with HF but were hampered
by methodological problems, sample size, or both. For exam-
ple, Lopez et al.6 have tried to extrapolate skeletal muscle
mass using abdominopelvic computed tomography scans per-
formed during an acute hospitalization in order to diagnose
sarcopenia in 160 patients with HF, and they observed a
4.5-fold increase in the risk of death in those patients labelled
as sarcopenic. However, it is difficult, if not impossible, to use
abdominopelvic imaging to understand appendicular skeletal
muscle mass. Recently, this approach has been discouraged,
as it may be a ‘flawed premise’.25 Apart from this, the area
of interest, psoas muscle, can be assessed by the volume of
the entire muscle, its unidimensional thickness, its
cross-sectional area either unadjusted in cm2, normalized to
patient height, normalized to body surface area, or normal-
ized to the area of the adjacent vertebral body.25 Thus, even
though these authors identified low psoas muscle area in pa-
tients with chronic HF after an acute hospitalization as an in-
dependent predictor of death, these findings should not be
extrapolated to the skeletal muscle mass of the extremities.
Very similarly, Tsuji et al.5 examined psoas muscle mass in
78 patients undergoing left ventricular assist device implanta-
tion. They found that perioperative muscle wasting as extrap-
olated from the psoas measurement approach was
associated with higher mortality in their patient cohort.
Nichols et al. used DEXA scanning in 60 male patients with
coronary heart disease and found that 13 of these (21.7%)
had low skeletal muscle mass, as defined using a skeletal
mass index <7.26 kg/m2 or appendicular skeletal mass
<25.72%. In this comparatively small cohort of patients with-
out HF, lower skeletal muscle mass was associated with a
higher risk of all-cause mortality. Tsuchida and colleagues
found a sarcopenia prevalence of 52.6% among 38 patients
with acutely decompensated HF but mainly used sarcopenia
as a predictor of high BNP levels.7
Our findings from patients with HF call for closer scrutiny
of skeletal muscle and also for a wider availability of DEXA
scanning. As mentioned, previous studies have been
hampered by methodological problems, because DEXA
scanning is not routinely available in many hospitals.
Computed tomography and magnetic resonance imaging
are alternatives, but the assessment of appendicular skele-
tal muscle with these imaging techniques is not common
for reasons of radiation exposure, time restrictions, or
cost/reimbursement issues. DEXA scanning, on the other
hand, is a very quick alternative (scanning time less than
2 min) that provides crucial information about a patient’s
body composition in the limbs as well as in the whole body.
It is comparatively cheap and simple to handle. It remains a
matter of speculation if screening tools such as the SARF-F
questionnaire or skinfold measurements can identify pa-
tients with HF in need of DEXA scanning or other imaging
techniques, which would make patient selection even
Table 2 Patients’ characteristics by muscle status
Without muscle
wasting (n = 221)
With muscle
wasting (n = 47) P-value
Age (years) 66.12 ± 11.04 71.94 ± 8.60 0.001
Sex (% female)55 (24.9%) 2 (4.3%) 0.001
Iron deficiency
(%)
103 (46.8%) 34 (72.3%) 0.002
Anaemia (%) 59 (26.7%) 22 (46.8%) 0.009
NYHA class 2.29 ± 0.60 2.47 ± 0.72 0.1
GFR (CKD-EPI,
mL/min)
59.80 ± 14.93 59.05 ± 14.53 0.8
NT-proBNP
(ng/L)
1272 ± 2469 2459 ± 3467 <0.001
Albumin (g/L) 37.26 ± 3.62 36.09 ± 4.27 0.055
Transferrin
(mg/dL)
267.81 ± 45.64 280.23 ± 63.29 0.207
CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; GFR,
glomerular filtration rate; NT-proBNP, N-terminal pro-B-type natri-
uretic peptide; NYHA, New York Heart Association.
FIGURE 1 Kaplan–Meier survival curves by status of muscle wasting in
the overall cohort.
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easier.26,27 Patients with low skeletal muscle, that is,
sarcopenia or at risk of muscle loss (pre-sarcopenia),28
may benefit from more aggressive HF therapies, because
retrospective analyses have highlighted the importance of
using standard HF medications like beta-blockers or
angiotensin-converting enzyme inhibitors in these
patients.29,30 Additional treatment approaches include ex-
ercise training (endurance exercise, muscle strength train-
ing, and inspiratory muscle training), nutritional support
(e.g. high-calorie nutritional supplements and
branched-chain amino acids),31–33 and possibly anabolic
substances.4,34,35 Unfortunately, none of these interven-
tions have been tested in prospective randomized con-
trolled trials of adequate size so far, but smaller trials
suggest that exercise training improves quality of life and
the distance covered during the 6 min walk test.12
Taken together, muscle wasting beyond the cut-offs de-
fined to identify sarcopenia identifies a large proportion of
patients with HF who have low muscle strength, quality of
life, and exercise capacity and who are likely to become frail
in that they may be at increased risk of falling, risk of frac-
tures, and hospitalizations. Our data show that these patients
are also at two-fold increased risk of death, an effect primar-
ily driven by events in patients with HFrEF. Future studies are
needed to better understand this effect in patients with
HFpEF, because the event rate in this subgroup of our study
population remained small.
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Creatinine (per 1 unit
increase)
2.231.60–3.0923.43<0.0011.941.12–3.385.51 0.01927.574.19–181.5411.890.0011.340.73–2.480.890.345
Log NT-proBNP (per 1 SD
increase)
2.041.58–2.6231.32<0.0011.220.85–1.751.15 0.284 0.880.37–2.11 0.080.7801.450.94–2.232.880.090
Iron deficiency (present) 1.621.07–2.45 5.27 0.0231.080.64–1.810.08 0.772 1.990.58–6.82 1.190.2760.910.50–1.650.090.759
Muscle wasting (present) 1.981.25–3.13 8.88 0.0031.801.01–3.194.04 0.044 1.860.32–10.70 0.480.4891.971.05–3.714.450.035
HFpEF vs. HFrEF 0.370.22–0.6314.60<0.0010.560.20–1.601.1640.281
χ2 model = 60.55 χ2 model = 29.17 χ2 model = 32.56
CI, confidence interval; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HR, hazard
ratio; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association;
SD, standard deviation.
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